Skip to main content
×
×
Home

Diabetes and its prevention: Pragmatic solutions for people with schizophrenia

  • Stephen Gough (a1) and Robert Peveler (a2)
Abstract
Background

Patients with schizophrenia have an increased risk of developing diabetes. However, no pragmatic pathway of care has ever been proposed in order to identify individuals at risk and manage that risk effectively.

Aims

To develop practical recommendations for the screening and management of diabetes in schizophrenia.

Method

Staged review of evidence for the under recognition of diabetes in people with schizophrenia and of the applicability of current screening strategies to this population. Recommendations for pragmatic pathways of care were developed.

Results

All patients with schizophrenia should be screened and managed as a high-risk group for the development of diabetes. Psychiatrists should be responsible for screening and diabetes risk management; primary care physicians and/or diabetologists should be responsible for managing diabetes. Choice of antipsychotics should be based on achieving good control of schizophrenia, which may improve compliance with diabetes risk reduction strategies.

Conclusions

Effective multi-disciplinary team working should reduce the burden of diabetes in schizophrenia.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Diabetes and its prevention: Pragmatic solutions for people with schizophrenia
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Diabetes and its prevention: Pragmatic solutions for people with schizophrenia
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Diabetes and its prevention: Pragmatic solutions for people with schizophrenia
      Available formats
      ×
Copyright
Corresponding author
Dr S. C. L. Gough, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK. Tel: (0) 121 4243593; fax: (0) 121 4240593; e-mail: s.c.gough@bham.ac.uk
Footnotes
Hide All

Declaration of interest

S.G. has received financial support from Aventis, Eli Lilly, GSK, Novo Nordisk, Takeda and Novartis. R.P. has received financial support from Eli Lilly, Astra Zeneca, Janssen-Cilag, Organon, Synthélabo, GSK, Pfizer, Wyeth and Lundbeck.

Footnotes
References
Hide All
Alberti, K. G. (1996) The clinical implications of impaired glucose tolerance. Diabetic Medicine, 13, 927937.
American Diabetes Association (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 20, 11831197.
Amos, A. F., McCarty, D. J., Zimmet, P., et al (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine, 14 (suppl. 5), S185.
Brown, S., Birtwistle, J., Roe, L., et al (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697701.
Cheta, D., Dumitrescu, C., Georgescu, M., et al (1990) A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes and Metabolism, 16, 1115.
Chiasson, J. L., Josse, R. G., Gomis, R., et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 359, 20722077.
Citrome, L. & Volavka, J. (2002) Atypical antipsychotics: a revolutionary or incremental advance? Expert Review of Neurotherapeutics, 2, 6988.
Cohn, T., Wolever, T., Zipursky, R., et al (2002) Screening for diabetes and impaired glucose tolerance in patients on antipsychotic medication. International Journal of Neuropsychopharmacology 5 (suppl. 1), S168.
Cunningham, F., Lambert, B., Dalack, G., et al (2003) Diabetes associated with antipsychotic use in veterans with schizophrenia. Pharmacoepidemiology and Drug Safety, 12 (suppl. 1), S154S155.
Davidson, M. B., Schriger, D. L., Peters, A. L., et al (1999) Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA, 281, 12031210.
Department of Health (2002) The National Service Framework for Diabetes. http://www.doh.gov.uk/nsf/diabetes/
Diabetes UK (2000) Care Recommendation. New Diagnostic Criteria for Diabetes. http://www.diabetes.org.uk/infocentre/carerec/newdiagnotic.htm
Diabetes UK (2002) Early Identification of People with Type 2 Diabetes. http://www.diabetes.org.uk/infocentre/state/downloads/earlyid.doc
Dixon, L., Weiden, P., Delahanty, J., et al (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26, 903912.
Dynes, J. B. (1969) Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Diseases of the Nervous System, 30, 341344.
Forrest, R. D., Jackson, C. A. & Yudkin, J. S. (1986) Glucose intolerance and hypertension in north London: the Islington Diabetes Survey. Diabetic Medicine, 3, 338342.
Green, M. (2003) Managing schizophrenia in patients with co-morbid diabetes. European Neuropsychopharmacology, 13 (suppl. 4), S306.
Henderson, D. C. (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 16, 7789.
Keskiner, A., El Toumi, A. & Bousquet, T. (1973) Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics, 14, 176181.
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346, 393403.
Lindenmayer, J.-P., Czobor, P., Volavka, J., et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160, 290296.
Meigs, J. B., Muller, D. C., Nathan, D. M., et al (2003) The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes, 52, 14751484.
Mukherjee, S., Schnur, D. B. & Reddy, R. (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet, i, 495.
Mukherjee, S., Decina, P., Bocola, V., et al (1996) Diabetes mellitusin schizophrenic patients. Comprehensive Psychiatry, 37, 6873.
National Institute for Clinical Excellence (2002) Management of Type 2 Diabetes – Blood Glucose (Guideline G). http://www.nice.org.uk/cat.asp?c=36733
National Institute for Clinical Excellence (2003) Guidance on the Use of Patient-Education Methods. Models for Diabetes. Health Technology Appraisal. London: NICE.
Perry, R. C., Shankar, R. R., Fineberg, N., et al (2001) HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care, 24, 465471.
Ryan, M. C. & Thakore, J. H. (2002) Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences, 71, 239257.
Sernyak, M. J., Leslie, D. L., Alarcon, R. D., et al (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159, 561566.
Simmons, D., Williams, D. R. & Powell, M. J. (1991) The Coventry Diabetes Study: prevalence of diabetes and impaired glucose tolerance in Europids and Asians. Quarterly Journal of Medicine, 81, 10211030.
Sowell, M., Mukhopadhyay, N., Cavazzoni, P., et al (2003) Risk factors for diabetes during clinical trials of antipsychotics. Journal of Psychopharmacology, 17 (suppl.), A53.
Subramaniam, M., Chong, S.-A. & Pek, E. (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Canadian Journal of Psychiatry, 48, 345347.
Tuomilehto, J., Lindstrom, J., Eriksson, J. G., et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine, 344, 13431350.
UK Prospective Diabetes Study Group (1991) Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Research, 13, 111.
UK Prospective Diabetes Study Group (1995) Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes, 44, 12491258.
UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837853.
Wang, W., Lee, E. T., Fabsitz, R., et al (2002) Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care, 25, 13651370.
Warram, J. H., Sigal, R. J., Martin, B. C., et al (1996) Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabetic Medicine, 13 (suppl. 6), S4045.
World Health Organization (1999) Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/99.2. Geneva: WHO.
Yu, B. P., Ortiz, T., Chong, Y. S., et al (2002) Atypical antipsychotics in patients with diabetes mellitus: a retrospective review. Drug Benefit Trends, 14, 4245.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 42 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 20th June 2018. This data will be updated every 24 hours.

Diabetes and its prevention: Pragmatic solutions for people with schizophrenia

  • Stephen Gough (a1) and Robert Peveler (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *